Stevenage | Jotup

Cellular Origins and Cell and Gene Therapy Catapult Collaborate to Demonstrate Universal Automation of CGT Manufacturing

Retrieved on:

星期三, 五月 29, 2024

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, today announced a collaboration to demonstrate universal automation of CGT manufacturing.

Key Points:

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, today announced a collaboration to demonstrate universal automation of CGT manufacturing.
The partnership will undertake the physical and digital integration of existing bioprocessing equipment at the CGT Catapult’s Stevenage Manufacturing Innovation Centre (MIC) using Cellular Origins’ robotic platform, Constellation™.
2023 was a landmark year for the CGT industry, further demonstrating the growing need to scale CGT manufacturing.
CGT Catapult’s experience in establishing GMP facilities and optimising cell therapy manufacture is directly aligned with Cellular Origins’ mission to prove the impact automated manufacturing can have in transforming cell therapy production.

Charles River Announces Opening of RightSourceSM Laboratory, Supporting Stevenage Biocluster

Retrieved on:

星期一, 九月 25, 2023

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the opening of another RightSourceSM facility, and first in the United Kingdom, which will provide services to the Stevenage advanced therapies biocluster.

Key Points:

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the opening of another RightSourceSM facility, and first in the United Kingdom, which will provide services to the Stevenage advanced therapies biocluster.
RightSource is a flexible biologics testing lab , operated and managed by Charles River, making fast, reliable quality control (QC) more accessible to a broader reach of companies.
This platform-based QC lab will be operated by Charles River employees who will utilize Charles River’s quality management systems, test methods, and standard operating procedures (SOPs) to support QC testing needs.
Unlike standard insourcing solutions, RightSource offers clients the complete Charles River package of proprietary assays with all of the associated quality, scientific, and digital platforms.

Givex Corp. Announces Counter Solutions Subsidiary Named Top Supplier Retail 2023 in Best In-Store Solution Category at reta awards

Retrieved on:

星期二, 二月 28, 2023

Pleasure, KDS, Marks & Spencer, TSX, Partnership, M&S, Digital, Coffeehouse, Sale, EuroShop, Cryptocurrency, Stevenage

Counter Solutions' technology within Marks & Spencer's digital cafe at Stevenage includes kiosks, WAY2PAY kiosks, online ordering, Kitchen Display Systems (KDS) and stock management

Key Points:

Counter Solutions' technology within Marks & Spencer's digital cafe at Stevenage includes kiosks, WAY2PAY kiosks, online ordering, Kitchen Display Systems (KDS) and stock management
TORONTO, Feb. 28, 2023 /PRNewswire/ - Givex Corp. (TSX: GIVX) (OTCQX: GIVXF) announced today that Counter Solutions Holdings Limited ("Counter Solutions"), a subsidiary in the Givex group, as the technology partner of Marks & Spencer, has been named Top Supplier Retail 2023 in the category Best In-Store Solution at the reta awards by EHI Retail Institute.
On February 27th, 2023, the winners were honored at an evening event at Dr. Thompson's Seifenfabrik in Düsseldorf.
Counter Solutions, which was acquired by Givex UK Corporation Limited in August 2022 , has been the technology partner of Marks & Spencer since 2021.
Marks & Spencer's new digital cafes are outfitted with Counter Solutions' WAY2PAY self-order kiosk, stock management and kitchen automation solution.

Givex Corp. Announces Counter Solutions Subsidiary Named Top Supplier Retail 2023 in Best In-Store Solution Category at reta awards

Retrieved on:

星期二, 二月 28, 2023

Pleasure, KDS, Marks & Spencer, TSX, Partnership, M&S, Digital, Coffeehouse, Sale, EuroShop, Cryptocurrency, Stevenage

TORONTO, Feb. 28, 2023 /PRNewswire/ -- Givex Corp. (TSX: GIVX) (OTCQX: GIVXF) announced today that Counter Solutions Holdings Limited ("Counter Solutions"), a subsidiary in the Givex group, as the technology partner of Marks & Spencer, has been named Top Supplier Retail 2023 in the category Best In-Store Solution at the reta awards by EHI Retail Institute. On February 27th, 2023, the winners were honored at an evening event at Dr. Thompson's Seifenfabrik in Düsseldorf.

Key Points:

Counter Solutions' technology within Marks & Spencer's digital cafe at Stevenage includes kiosks, WAY2PAY kiosks, online ordering, Kitchen Display Systems (KDS) and stock management
TORONTO, Feb. 28, 2023 /PRNewswire/ -- Givex Corp. (TSX: GIVX) (OTCQX: GIVXF) announced today that Counter Solutions Holdings Limited ("Counter Solutions"), a subsidiary in the Givex group, as the technology partner of Marks & Spencer, has been named Top Supplier Retail 2023 in the category Best In-Store Solution at the reta awards by EHI Retail Institute.
On February 27th, 2023, the winners were honored at an evening event at Dr. Thompson's Seifenfabrik in Düsseldorf.
Counter Solutions, which was acquired by Givex UK Corporation Limited in August 2022 , has been the technology partner of Marks & Spencer since 2021.
Marks & Spencer's new digital cafes are outfitted with Counter Solutions' WAY2PAY self-order kiosk, stock management and kitchen automation solution.

Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

星期一, 十二月 6, 2021

Company, Research, GLOBE, Gaucher's disease, Fabry disease, American, Patient, Transgene, Fabry, MD, Employment, AAV, Nasdaq, Pharmaceutical industry

The awards were granted pursuant to the terms of Freelines 2021 Equity Inducement Plan, which was adopted by Freelines board of directors inSeptember 2021.

Key Points:

The awards were granted pursuant to the terms of Freelines 2021 Equity Inducement Plan, which was adopted by Freelines board of directors inSeptember 2021.
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies.
The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases.
Freeline is headquartered in the UK and has operations in Germany and the US.

Freeline to Participate in Evercore ISI 4th Annual HealthCONx Conference

Retrieved on:

星期二, 十一月 23, 2021

Patient, Fireside, Conference, Company, Fireside chats, Evercore, Haemophilia, Transgene, Investor, Fabry, EST, Nasdaq, Research, GLOBE, Fabry disease, Gaucher's disease, AAV, Vaccine

LONDON, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will participate in the Evercore ISI 4th Annual HealthCONx Conference.

Key Points:

LONDON, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will participate in the Evercore ISI 4th Annual HealthCONx Conference.
Freeline Chief Executive Officer Michael Parini is scheduled to participate in a Fireside Chat at the event on December 2, 2021 at 3:55 p.m. EST.
A webcast of the Fireside Chat will be available on the Investors section of the Freeline website for approximately 90 days.
Senior management will participate in virtual one-on-one meetings with investors throughout the conference.

Freeline to Participate in Stifel 2021 Virtual Healthcare Conference

Retrieved on:

星期三, 十一月 10, 2021

Investor, Fireside chats, Fabry, Transgene, Gaucher's disease, Fabry disease, Research, Fireside, Conference, Company, GLOBE, Nasdaq, Patient, AAV, Vaccine

LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will participate in the Stifel 2021 Virtual Healthcare Conference.

Key Points:

LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will participate in the Stifel 2021 Virtual Healthcare Conference.
Freeline Chief Executive Officer Michael Parini is scheduled to participate in a Fireside Chat at the event on November 15, 2021 at 1:20 p.m.
A webcast of the Fireside Chat will be available on the Investors section of the Freeline website for 90 days.
Senior management will participate in virtual one-on-one meetings with investors at the conference on November 16.

Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results

Retrieved on:

星期二, 十一月 9, 2021

LONDON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced new data from its ongoing Phase 1/2 MARVEL-1 dose-finding clinical trial of FLT190 for the treatment of Fabry disease and provided updates on its pipeline programs. The Company also announced that Pamela Foulds, MD has been appointed as Chief Medical Officer (CMO) and reported financial results for the third quarter of 2021.

Key Points:

The Company also announced that Pamela Foulds, MD has been appointed as Chief Medical Officer (CMO) and reported financial results for the third quarter of 2021.
This step is consistent with the recommendation of our independent Data Monitoring Committee, with whom we have worked to review the data.
Freeline continues to anticipate interim data readouts from the MARVEL-1 trial in 2022, sharing further efficacy and safety data.
Today the Company announced the expansion and strengthening of its executive leadership team with the appointment of Pamela Foulds, MD as Chief Medical Officer.

Freeline Therapeutics to Present FLT180a Data at the 2021 ASH Annual Meeting

Retrieved on:

星期四, 十一月 4, 2021

The abstract accepted for presentation is listed below and can be viewed online in the ASH conference program.

Key Points:

The abstract accepted for presentation is listed below and can be viewed online in the ASH conference program.
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies.
The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases.
The Company has clinical programs in hemophiliaB and Fabry disease, as well as preclinical programs in Gaucher disease Type 1 and hemophiliaA.

Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

星期三, 十一月 3, 2021

Fabry disease, Research, Daimler Freeline, Patient, Fabry, Gaucher's disease, Company, RSU, Transgene, American, Nasdaq, Employment, GLOBE, AAV, Pharmaceutical industry

The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by an independent subcommittee of the remuneration committee of Freelines board of directors.

Key Points:

The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by an independent subcommittee of the remuneration committee of Freelines board of directors.
The awards were granted pursuant to the terms of Freelines 2021 Equity Inducement Plan, which was adopted by Freelines board of directors inSeptember 2021.
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies.
Freeline is headquartered in the UK and has operations in Germany and the US.